Allogeneic bone marrow transplant followed by donor lymphocyte infusion (DLI) is limited by T cell-mediated graft-versus-host disease (GVHD). A potential solution to alleviate uncontrolled GVHD is to create a controllable suicidal lymphocyte using retroviral transduction of the herpes simplex virus thymidine kinase gene (HSVtk) into the T cell graft. Should GVHD arise, the administration of ganciclovir (GCV) should eliminate the causal T cells. The culture conditions and expansion protocols required to produce suicidal lymphocytes may affect the composition of the T cell product. In this report we describe how T cells from individual donor samples respond to the same culture condition in highly varied ways. However, the ability to utilize transplantation and the GVL effect are limited by the development of graft-versus-host disease (GVHD), which is also initiated by T cells. Since GVHD can cause great morbidity and/or mortality, patient eligibility for transplantation has traditionally been limited to patients under 60 years of age with complete HLA matched donors. This restricts the ability to attempt to generate a GVL effect to a minority of leukemia patients. Lacking the ability to selectively eliminate the causative T lymphocytes after infusion, therapy for the prevention of GVHD has relied on immunosuppressive agents, which further contribute to infection and mortality. While substantial efforts have been made to separate GVL from GVHD, these have yet to be fully effective. Many of these efforts have attempted to deplete a particular lymphocyte subset but results have been inconsistent as to which subset is important. Depletion of CD8 cells resulted in decreased GVHD with the preservation of GVL in CML but not in other types of leukemia. 4 In various murine models depletion of CD4, CD8 or murine NK lymphocytes has resulted in decreased incidence of GVHD with preservation of GVL. 5, 6 In an attempt to control severe GVHD by a novel mechanism, recent efforts have included modifying the transplanted T cell ex vivo by retrovirus-mediated transfer of the herpes simplex virus thymidine kinase (HSVtk) gene to create controllable suicidal lymphocytes.
However, the ability to utilize transplantation and the GVL effect are limited by the development of graft-versus-host disease (GVHD), which is also initiated by T cells. Since GVHD can cause great morbidity and/or mortality, patient eligibility for transplantation has traditionally been limited to patients under 60 years of age with complete HLA matched donors. This restricts the ability to attempt to generate a GVL effect to a minority of leukemia patients. Lacking the ability to selectively eliminate the causative T lymphocytes after infusion, therapy for the prevention of GVHD has relied on immunosuppressive agents, which further contribute to infection and mortality. While substantial efforts have been made to separate GVL from GVHD, these have yet to be fully effective. Many of these efforts have attempted to deplete a particular lymphocyte subset but results have been inconsistent as to which subset is important. Depletion of CD8 cells resulted in decreased GVHD with the preservation of GVL in CML but not in other types of leukemia. 4 In various murine models depletion of CD4, CD8 or murine NK lymphocytes has resulted in decreased incidence of GVHD with preservation of GVL. 5, 6 In an attempt to control severe GVHD by a novel mechanism, recent efforts have included modifying the transplanted T cell ex vivo by retrovirus-mediated transfer of the herpes simplex virus thymidine kinase (HSVtk) gene to create controllable suicidal lymphocytes. 7 Cells that express the HSVtk gene are able to metabolize ganciclovir (a nucleoside analog) into GCV-monophosphate and subsequently into GCV-triphosphate by endogenous mammalian kinases. 8 GCV-triphosphate is a chain terminating nucleoside and a potent inhibitor of viral DNA polymerase, both modes of action resulting in premature apoptosis of the transduced populations. 9, 10 In this strategy HSVtk containing T cells are infused in traditional settings but, should GVHD arise, the causal T cell is selectively eliminated by the administration of GCV resulting in the cessation or control of GVHD. Results from a recent clinical trial have confirmed the ability to produce HSVtk-transduced lymphocytes, their ability to cause both GVL and GVHD after reinfusion, and the ability to eliminate these T cells and the GVHD by the administration of GCV. 11 Production of HSVtk-transduced lymphocytes requires ex vivo culture, stimulation, transduction and selection. However, the effect of the production process on the immune function and the lymphocyte subset composition (LSC) (ratios of CD3 ϩ /CD4 ϩ , CD3 ϩ /CD8 ϩ and CD56 ϩ lymphocytes) has not been determined. While T cell growth factors, such as IL-2, and the use of potent mitogenic stimulators permit the expansion of T cells the repertoire can be dramatically affected by the stimulation agents used. [12] [13] [14] [15] One report by Townsend and Simon 16 suggests that higher (Ͼ500 U/ml) IL-2 concentrations support growth of CD3 ϩ /CD4 ϩ T cells, while other reports suggests that the use of lower concentrations (Ͻ100 U/ml) support growth of CD3 ϩ /CD8 ϩ T cells. 17, 18 Others suggest that mitogenic stimulators such as OKT-3, PNA, PHA, and concanavalin A can cause preferential expansion of CD4 ϩ or CD8 ϩ /56 ϩ subpopulations. 15, 19, 20 While it is unknown what T cell subtype population is responsible for GVL and GVHD, it may be desirable in the DLI setting to try to provide a graft product with a full complement of T cells (both CD4/CD8) since grafts containing full T cell repertoires are able to induce remissions.
In preparation for clinical use of suicidal lymphocytes we evaluated conditions to optimize their production and studied the effect of the production process on the immune function and the LSC of the product. We observed that not only does the culture medium composition affect the LSC but that individual donor samples grown in the same culture media respond with unique expanded T cell populations. We show that these production methods result in large numbers of tk-transduced lymphocytes (Tk-T cells) and that the transduction protocol does not affect the cytotoxic functions as tested by 51 Cr release assay. As a way to counteract the varied T cell composition of the patient samples after culture, we describe a method to sequentially preselect the donor's T cells into CD3 ϩ /CD4 ϩ or CD3 ϩ /CD8 ϩ specific populations prior to culture and demonstrate that these preselected T cells maintain their specific phenotype after the 14 day culture period.
Materials and methods

Lymphocyte culture
Peripheral blood samples from normal donors were subjected to gradient separation using Ficoll (Lymphocyte Separation media, Oraganon Teknika Corp, Durham, NC, USA) and the peripheral blood mononuclear cells (PBMC) were isolated. These cells were enumerated and cultured at 1 ϫ 10 6 cells/ml in AIM-V (GibcoBRL, Grand Island NY, USA) with 5% heat inactivated donor A/B serum which contained 500 U/ml of IL-2 (Cetus, Thousands Oaks, CA, USA). On day 1 300 ng/ml of anti-CD3 antibody (OKT3, Ortho-Biotech, NJ, USA) was added to stimulate the lymphocytes to divide. The medium was also supplemented with 1ϫ glutamine/penicillin/streptomycin (Biowhittaker, Walkersville, MD, USA) and 1ϫ gentamycin sulfate (GibcoBRL, Grand Island, NY, USA). The cells were cultured in Baxter Lifecell 1000 ml bags at 37°C in 5% CO 2 for a period of 21 days, during which time the cells were transduced, selected and expanded. The average number of PBMC after Ficoll preparation was 1 ϫ 10 8 cells (of which approximately 25% were T cells (unpublished data)). These cells were utilized in the experiments described below. We utilized three media which were described for use in T lymphocyte culture, AIM V, X-VIVO 20 (Biowhittaker), and RPMI 1640 (Cellgro, VA, USA), all supplemented with heat inactivated 5% human A/B donor serum. [21] [22] [23] Also tested was X-VIVO 20 in the absence of serum as this is described by the manufacturer as an optimal growth medium for T lymphocytes. Media were supplemented with additional IL-2 at 500 U/ml with each medium change or addition. The T cells were all grown for 14 days, with harvesting Ϯ magnetic antibody separation (MACS) selection followed by IL-2 and OKT3 stimulation on day 0, entry into growth phase on days 1-3, retroviral transduction on days 3-5, a day of rest on day 6, and selection with G418 during days 7-14 ( Figure 1 ). These media stimulation protocols, and cytokine cocktails result in cell populations which are composed entirely of T cells. We observed no B cells or monocytes/macrophages after 5 days of culture.
Transduction and G418 selection
The peripheral blood mononuclear cells cultured as described above were transduced with a retroviral vector that contains an SV40 promoter-driven neomycin resistance gene and the HSVtk gene driven by the retroviral LTR promoter (G1TkSvNa.7, a generous gift of Genetic Therapy Incorporated, Gaithersburg, MD, USA a Novartis company). 22 Briefly, 2 ϫ 10 8 stimulated T cells were resuspended in 5 ml of complete medium and diluted to the correct concentration by addition of concentrated viral supernant keeping the multiplicity of infection (MOI) at 10:1. Protamine sulfate (10 g/ml) was added and the cells were mixed and allowed to incubate with the virus for 6 h. Fresh viral supernatant was added daily for 3 consecutive days on days 3, 4 and 5 of culture. Forty-eight hours after the third infection, the cells were resuspended in fresh complete medium containing 700 U/ml of G418 (GibcoBRL, Grand Island NY, USA) (approximately 705 active units) for 7 days (days [7] [8] [9] [10] [11] [12] [13] [14] . This culture was designated as the 'bulk' population since the whole PBMC was processed together. As a control, bulk populations of the same donors PBMC were grown and manipulated similarly but were not transduced (treated with DMEM medium for 3 consecutive days) and selected (fed medium not containing G418), this was designated the 'mock' infected and 'mock' selected populations. Cells were then tested for transduction efficiency, immune function and LSC (day 14). Figure 1 Production schedule for generating suicidal lymphocytes. To produce the tk-transduced T lymphocytes we followed a 14 day schedule. Day 1: PBMC were phlebotomized from patients, Ficoll preparations were made of PBMC, and they were cultured in the presence of IL-2/OKT3. Days 3-5: static infection for 6 h daily (ϫ3). Day 6: rest period for 24 h. Days 7-14: selection of cells in 700 U/ml G418. FACS analysis was performed on day 1, 7 and 14.
Fluorescence-activated cell sorting (FACS) analysis
Lymphocytes were centrifuged, and 1 ϫ 10 6 cells were stained with 10 l of antibody, and incubated on ice for 30 min (manufacturer's protocol). Cells were then washed and resuspended in 1 ml of phosphate-buffered saline, and analyzed. Phenotype analysis was performed on a Becton Dickinson FACScan (Bector Dickinson, San Jose, CA, USA) using monoclonal antibodies to CD3, CD4, CD8 and CD56 (Becton Dickinson). FACS analysis was conducted on day 0 post phlebotomy and Ficoll separation, on day 7, after transduction but before selection, and on day 14, after selection.
GCV killing assay
Tranduced lymphocytes (1 ϫ 10 6 ml) were grown in 12-well tissue culture dishes (Costar, Cambridge, MA, USA), containing 2.5 ml of complete medium. Two of the three replicate wells received GCV on day 1 at concentrations of 5 m, 50 m or 500 m: the fourth well was given medium containing PBS and used as an control. Cells were incubated for 7 days and 100 l of cell suspension was removed. The cell concentration and viability were determined using the trypan blue exclusion test on days 3 to 7. For this, cells were removed from the 12-well dishes on selected days, and mixed with a 0.4% solution containing trypan blue (GibcoBRL). The cells were then assessed under 100ϫ magnification and all cells which were blue were scored as dead.
Cytotoxic activity of Tk-T cells
One of our concerns in determining the cytotoxic activity and immune function of these Tk-T cells, is that they are grown and expanded in the presence of IL-2 and OKT-3, resulting in highly activated T cells. Therefore, we utilized an immune assay that would demonstrate their functional ability to kill rather than relying on more conventional assays that measure activation and expansion, such as the mixed lymphocyte reaction (MLR) or 3 H-thymidine uptake. We determined the cytotoxic capacity of the Tk-T cells after culture, infection, and selection utilizing the 51 Cr release assay. Briefly, target cells (RAJI, K562) were labeled with 51 Cr for 30 min followed by two washes to remove excess 51 Cr. The correct cell numbers were aliquoted into 96-well dishes, and to each well the correct ratio of Tk-T cells (or mock infected as control). Effector to target ratios of 50:1 and 100:1 were tested. The reaction was allowed to proceed for 4 h and the reaction was centrifuged and the supernatant counted. The percent of specific lysis was calculated as total counts (experimental c.p.m. Ϫ spontaneous release/maximum c.p.m. Ϫ spontaneous c.p.m.).
Sequential MACS cell sorting
To pre-select specific populations of T cells prior to culture, we utilized the magnetic antibody cell sorting (MACS-Miltenyi Biotec, Auburn, CA, USA) technique. 24 Briefly, we developed a sequential sorting methodology to optimize the , 0.5% BSA, 0.6% acid citrate dextrose-A (ACDA), 100 /ml heparin, 100-200 U/DNase (added directly before use)) for 30 min at 4°C (20 l microbeads/10 7 cells), then reacted with the magnetic column (flow through collected). After three column washes in MACS buffer (flow through collected), the column was removed from the magnet and the magnetically retained cells were eluted and collected. The flow through cells were then concentrated and reacted with the Miltenyi anti-CD8 supermagnetic colloid for 30 min on ice, and the procedure repeated, following the instructions above. After all the CD4 ϩ /CD8 ϩ cells were eluted and collected, a sample was removed from each fraction and reacted with antimouse IgG-FITC and analyzed by FACS to determine the purity and recovery.
Results
Optimization of culture conditions for human peripheral blood lymphocytes
Retroviral transduction requires dividing cells. Consequently, for the creation of suicidal lymphocytes we had to ensure that we had the maximal number of stimulated (ie cycling) T cells available. 25 We tested a series of serumsupplemented and one serum-free medium to determine which would give the largest cell number and quickest expansion. Currently, RPMI is described as an optimal medium for creation of tk-expressing T cells by Tiberghien et al. 23 We also tested AIM-V, X-VIVO 20 and RPMI all supplemented with 5% heat-inactivated human A/B serum. All cells were fed with medium containing 500 IU/ml of IL-2 and given 5 g/ml of OKT3 on day 1. After this all cells were fed medium containing only IL-2. As shown in Figure 2 , T cells proliferated in all the serum-supplemented 
Figure 2
Growth curves for human peripheral blood lymphocytes in different media. We tested three media supplemented with 5% human A/B serum, and one medium without serum supplementation, as described in Materials and methods. Cell counts were performed every other day, and cell numbers were determined/ml of medium. Cells were grown at 1 ϫ 10 6 cells/ml. Each point represents three wells. media tested, with the maximal growth achieved with AIM-V and X-VIVO 20. We noted a 20-fold increase in cell number during the 14 day growth period. T cells grown in RPMI did not expand as well as those grown in the other two media in our experiments, reaching approximately 15-fold expansion over the 14 day period. We noted the lowest and slowest growth with the non-serum-containing medium X-VIVO 20, which expanded similarly to the serum-supplemented medium but peaked at day 7 and plateaued over the next few days. These stimulated, expanded T cells were the starting product for the retroviral transductions.
Individual donor T cell subset compositions fluctuate in the same media
The effect of the stimulation, transduction, and expansion process on the repertoire and ratio of T cells has not been determined previously. In our initial experiments we observed that the LSC (CD4/8 ratios) varied among individual donors when grown in the same medium. If this was a consistent effect of the production process, the composition of the product delivered back to patients could be variable. Since the desired composition of lymphocytes for mediating GVL effects is not known, depletion of a particular subset could compromise clinical response. To determine the effect of the production process on LSC we evaluated T cell samples from five donors during the 14 day stimulation, infection, and selection process. Cells were removed and FACS analyzed for CD3, CD4, CD8 and CD56 on days 0 (starting day), 7 (post infection) and 14 (post selection). In Figure 3a , the top panel represents the 'bulk' control populations in which T cells were grown, mock infected, and mock selected during the 14 days. The lower panels represent the 'bulk' infected population in which cells were transduced on days 3-5, rested for 24 h then fed medium containing 700 g/ml of G418 on days 7-14. In both the bulk control and infected populations we noted that the LSC of three donors (TS, MA, AG) had a decrease in CD4 ϩ cell numbers during the 14 days period. One donor (VS) had a major increase in the number of CD4 ϩ cells for the first 7 days followed by a slight drop, and one donor had no change in the CD4 ϩ cell numbers over the 14 days. Comparing the bulk infected populations we noted a similar trend. Two donors (TS, AG) had a major decline in their CD4 ϩ population over the 14 days, while three donors (VS, MM, MA) had a major increase in the number of CD4 ϩ cells at the midpoint but these cell numbers reduced to essentially starting cell numbers by day 14. We observed very similar results for CD8 expression in the bulk control and bulk infected samples with all donors showing a slight increase in the numbers of CD8 ϩ cells by day 7. However 2 donor cultures ended with predominately CD8 ϩ T cells (MA, AG), while the remaining three donors had an increase in CD8 ϩ T cells to about 60-75% above their starting T cell numbers. Analyzing for CD56 we noted that most donor's CD56 ϩ T cells remained constant or decreased slightly during the 14 day testing period. We did however note that one donor (AG) had cells that were dual positive for CD8 and CD56.
Pre-selected T cell populations (CD4 ϩ /CD8 ϩ ) retain their phenotype even after 14 days
We hypothesized that interactions between different subsets affected each other in the bulk culture but that the subset drift would not be observed if the different subsets (ie either CD3 ϩ /CD4 ϩ or CD3 ϩ /CD8 ϩ ) were cultured in isolation from each other. To test this hypothesis that pre-selected CD4 ϩ or CD8 ϩ T cells will maintain their phenotype after the expansion, infection and selection process, CD4 or CD8 T cells were selected from the post-Ficoll PBMC population of three normal donors using the MACS system. A sequential sorting procedure was used as this yielded populations that were very pure while providing the highest recovery of T cells on day 1. After the separation procedure the cells were carried in separate bags but otherwise were handled identically to the 'bulk' cells. The LSC was determined after MACS separation and again on days 7 and 14. After 14 days in culture we noted that in the three donors tested, the individual populations retained their starting phenotype even after expansion, infection and selection unlike that of the 'bulk' populations ( Figure 3b ). The infection period during days 3-5 caused no deviation from the initial phenotype, nor did the selection procedure. Additional subset analysis of non-selected (bulk) or preselected CD3 ϩ /CD8 ϩ and CD3 ϩ /CD56 ϩ T cells, to identify natural killers (NK) cells generated during this procedure, reveals that our production process generates few NK cells.
In one donor (MM) the CD3
ϩ /CD8 ϩ T cells were approximately 24.87% of the bulk population, and 98.72% of the pre-selected T cell population on day 0, by day 14 the preselected population remained at 96.84% while the bulk population was 55.47%. The CD3 ϩ /CD56 ϩ populations, showed minimal change from 4.81% on day 0 to 5.53% by day 14 in the bulk population, and nearly doubled to 8.14% in the pre-selected CD3 ϩ /CD8 ϩ populations (Figure 4 ).
Selected Tk-T cells are killed by GCV
Transduction efficiency was assessed in five donors' samples by the extent of GCV-induced cell kill, which reflects the percentage of cells which express the HSVtk gene. This assay represents a biological test of transduction efficiency because GCV selection kills only the transduced cells, which express adequate levels of active HSVtk enzyme. Concentrations of GCV covering clinically obtainable levels (5 and 50 m) and suprapharmacological concentrations (500 m) were utilized. T cells, which were infected, and selected, were efficiently killed in the presence of clinically obtainable levels of GCV over a 7 day period (Figure 5a ). Approximately 75% of Tk-transduced lymphocytes from the bulk infected population were killed with 5 and 50 m GCV compared to~25% cell die off in the control population. The selected CD4 ϩ or CD8 ϩ Tktransduced T cells were also killed with equal efficiency in the presence of GCV where 72% and 74% of the infected population of CD4 or CD8 cells, respectively, were eradicated. All populations responded to the supralethal concentration of GCV (500 m) yielding more than 95% trypan blue positive cells by day 4, indicating that the T cells were still viable and susceptible to GCV exposure. We also We assayed five donor samples by FACS during production of the suicidal lymphocytes. Samples were removed at designated time points, day 0 (start day), day 7 (after infection but prior to selection) and day 14 (post selection). Individual donor results are displayed as % of specific population. Populations tested were CD4 ϩ , CD8 ϩ , CD56 ϩ . (Note: % of cells may add up to Ͼ100% as cells positive for more than one antigen may appear more than once.) (b) Pre-selected T cell populations (CD4 ϩ /CD8 ϩ ) retain their phenotype even after 14 days. Three donor samples were preselected into CD4 ϩ populations, or CD8 ϩ populations and Tk-T cells were generated as described in Materials and methods. On days 0, 7, 14 samples were removed for FACS analysis. Individual donor results are displayed as % of specific populations.
counted the total number of cells remaining during the GCV assay as a direct indicator of total reduction of cells transduced and killed. As shown in Figure 5b , using cells from the wells grown in medium plus 5 m GCV, we observed approximately 2 logs of total reduction (a decrease from 1.25 ϫ 10 6 cells/ml to 1.15 ϫ 10 4 cells/ml) of bulk transduced T cells during 6 days of the GCV assay, whereas the number of bulk control cells which were insensitive to GCV remained fairly constant during the 6 days (a 7-10% drop in cell number). Taken together these data suggest that the observed 2.0 log reduction in total cell number of transduced cells reflects an eradication of more than 99% of the bulk transduced population.
Functional activity of HSVtk-transduced T cells
Our concern was that the T cells (both Tk ϩ and control) were already activated (from growth in the presence of IL-2), and it was therefore very difficult to assess the cytotoxic capacity of these cells using a mixed lymphocyte reaction. We therefore tested the effects of culture, infection and selection on the ability of the Tk-T cells to kill MHC mismatched target cells utilizing the 51 Cr release assay. The donors' T cells were reacted with two target cells types, K562 and RAJI. As shown in Figure 6 , all three donors' cells maintained the ability to kill target cells after culture, transduction and selection. Donor 1 demonstrated specific ϩ /CD8 ϩ cells were analyzed after production (day 14) to determine CD8 ϩ /CD56 ϩ profile as described in Materials and methods.
cytotoxicity against both RAJI and K562 cells, which was approximately 80% the efficiency of control cells, whereas donor 2 reacted strongly against the target cells providing killing equivalent to 100-120% of that of control lymphocytes. Tk-transduced lymphocytes from donor 3 also reacted strongly against the K562 cells killing at 65-80% the efficiency of control populations. Interestingly, donor 3's T cells also reacted with greater than 100% control activity against the RAJI cells which tended to be less efficient targets that the K562 cells. This demonstrates that the Tk-T cells maintain their reactivity after the production process.
Discussion
Allogeneic bone marrow (allo-BMT) transplants have been demonstrated to cure about 35-45% of patients who receive them. Used early in the disease course, the therapy reduces the relapse rate, even in patients who are refractory to conventional chemotherapy. Some of the effects of allo-BMT derive from the immunologically mediated antileukemic effect, known as graft-versus-leukemia. Unfortunately, the beneficial GVL effect is often overshadowed by the occurrence of GVHD, in which the donated T cells attack the recipients' organs. This reaction is the major cause of morbidity and mortality in allo-BMT patients. Consequently, patients who undergo allo-BMT must receive immunosuppressive agents (such as cyclosporine, FK506, corticosteriods or methotrexate) to reduce the risk of developing GVHD. This also possibly reduces the effectiveness of the GVL effect. Currently, there is no selective method to control the fate of the T lymphocytes once infused, and therefore control of GVHD and/or GVL is nonspecific and suboptimal. The ability to control GVHD could be achieved if the causative cells could be selectively eliminated after transplantation. One approach to selectively control the transplanted T cells would be to pre-emptively incorporate a suicide gene into the lymphocytes ex vivo, prior to infusion. Should GVHD develop the causative cells could be eliminated by the administration of GCV. Since both the GVL and GVHD effect appear to be mediated by T lymphocytes it appears important to provide a full complement of T cells for transplant to ensure a strong reactivity. This approach has been tested in limited trials utilizing suicidal lymphocytes. Bonini et al 11 reported a study in which eight donors underwent Tk-transduced T lymphocyte infusions and, of three patients who developed GVHD, two were rapidly controlled with administration of GCV. Another study by Tiberghien and colleagues 23 reported control of GVHD by GCV administration when suicidal lymphocytes were used in conjunction with a T cell-depleted marrow at the time of initial transplant. These studies suggest that the T cells could be manipulated ex vivo, successfully transduced with a tk-bearing retrovirus and after reinfusion were sensitive to GCV administration. However, the effects of the culture conditions on the production of the suicidal lymphocytes, and the LSC composition after ex vivo manipulations has not been reported. In this study we examined the optimal culture conditions and the effects of producing the tk ϩ expressing suicidal lymphocytes, particularly on the lymphocyte subset composition (LSC), and its possible implications for use in a clinical trial.
In these studies the production process induced variable changes on the LSC with some donors dominated by CD8 ϩ cells while others had predominantly CD4 ϩ or CD56 ϩ and one donor had dual positive CD8 ϩ /CD56 ϩ lymphocytes. This effect would appear to be the result of the stimulation and culture process, rather than the retroviral transduction or selected process, as the bulk control and bulk infected samples were similar for each donor on day 14. It is unclear which subsets in what ratios are required to achieve the optimal GVL effect. Furthermore, it is likely that this will vary for different types of leukemia (CD4 ϩ cells for CML, CD8 ϩ for AML) and it may also vary in different settings, for example, lymphocyte administration during initial transplant vs the DLI setting. 26 Clinical efficacy of suicidal lymphocytes produced in bulk fashion may therefore suffer from delivery of a product of variable composition to patients. Some patients could receive an infusion devoid of a crucial subset while others could providentially receive a mixture more likely to produce a strong GVL effect. This could adversely influence the clinical response rate in trials of suicidal lymphocytes and could erroneously suggest a lack of GVL efficacy by the manipulated cells.
Fortunately, our studies also discovered a simple solution to this potential problem. Pre-selection by magnetic antibody sorting followed by separate processing of individual subsets, CD3 ϩ /CD4 ϩ , or CD3 ϩ /CD8 ϩ yielded stable populations with minimal subset drift. This protocol requires only one additional manipulation at the start of the production process so production of Tk-T cells in closed bag systems could still be utilized. 27 This new protocol provides new flexibility in delivering the graft product because the separately cultured cells could be recombined in desired ratios prior to reinfusion into patients. This would permit Tk-transduced lymphocytes were assayed for HSVtk activity by the GCV killing assay. T lymphocytes were plated into 12-well dishes and fed medium containing 5, 50, or 500 m of GCV or PBS (control) for 7 days. On days 3-7, cells were removed, mixed with 0.4% trypan blue and counted. Cell viability was determined by counting total number of blue (dead) cells/100 cells. Each data point represents the average of three wells. Each graph represents GCV killing in each specific population: 'bulk' control; 'bulk' infected, CD4 ϩ pre-selected; CD8 ϩ pre-selected cells. Error bars were not shown due to SEM being 10% or less. (b) Cell reduction during the GCV assay. Tk-T cells taken from the 5 m well of the GCV assay were assessed for total cell number. Cells were counted on each day of the GCV assay and the total number of cells remaining was calculated for both the bulk control and the bulk infected populations. Numbers on the y axis are in exponential format, ie 1.00E + 04 ϭ 1 ϫ 10 4 , etc.
the delivery of a homogeneous product to the patient in clinical trials of suicidal lymphocytes as opposed to the heterogeneous product likely to arise from bulk production. Additionally, should a better definition of the optimal subsets and ratios be determined then the mixture could be altered to equal the desired composition.
Since achieving high target cell doses of Tk-T cells could be difficult, the use of pre-selected cells could hinder the generation of adequate cell numbers. The pre-selection process yields approximately 50% of the starting number of CD4 ϩ cells. This loss could be countered without difficulty by collecting a larger number of cells in the initial phlebotomy or pheresis. In these studies the pre-selected cells expanded only 12-fold relative to the bulk population which expanded approximately 20-fold (data not shown) during the 14 day period. Again, starting with a larger size sample Figure 6 Functional activity of HSVtk-transduced T cells. We determined the cytolytic activity of the suicidal lymphocytes after production by the 51 Cr release assay (described in Materials and methods). Briefly, the target cells K562 or RAJI cells were incubated with 51 Cr, and then reacted with the correct ratio of Tk-T cells for 4 h. Each data point represents the average of three wells/T cell population. The data shown are the % activity compared to control T lymphocyte activity for three donors.
could compensate for this. Alternatively new media specifically designed to promote T cell growth and expansion have recently become available. 28 These media have improved expansion of murine cells from 7-fold (obtained using standard media) to 230-fold and maintained better viability for 30 days in our hands (unpublished data). The use of improved media could also eliminate the cell number problem.
The utilization of controllable suicidal lymphocytes for managing GVHD is reaching clinical trials. These genemodified T cells have the potential to allow full modulation of alloreactivity against tumors (leukemias as well as solid tumors; a graft-versus-tumor effect), with minimal concern about uncontrolled GVHD. However, the reinfused product must be evaluated fully before trials commence not only for safety purposes but also to ensure a comprehensive graft. From the data presented, the culture conditions appear to influence the lymphocyte products' outcome uncontrollably, and we suggest the pre-selection of T cells before culture and transduction. This pre-selection will ensure the consistency of the graft product. Additionally, pre-selection will allow a 'mix-and-match' composition of Tk-T cell ratios to allow a unique tailoring to any possible CD4 ϩ /CD8 ϩ cell combination.
